Physician profile
Robert R Brown
NPI 1487610879
$3,097.38
in general payments reported to CMS, 2019-2025
28 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $38.01 · 2023: $767 · 2024: $640 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Education: $88.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.78 |
| Education | $88.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $324.35 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $294.91 | 2023-2025 | |
| Alkermes, INC. | $195.08 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $148.35 | 2025 | Auvelity |
| Novo Nordisk INC | $135.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.31 | 2025 | Caplyta |
| Akebia Therapeutics INC | $125.00 | 2021 | |
| Lilly USA, LLC | $122.47 | 2022-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $104.45 | 2023-2024 | |
| Glaxosmithkline, LLC. | $101.30 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $99.96 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $99.66 | 2025 | Fanapt |
| Astellas Pharma US INC | $84.99 | 2025 | |
| Pfizer INC. | $57.52 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.41 | 2025 | Trintellix |
| Corium, LLC | $45.69 | 2024-2025 | Azstarys |
| Lundbeck LLC | $45.57 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $37.12 | 2023 | Verquvo, Belsomra, Steglatro |
| Ardelyx, INC. | $32.66 | 2025 | Ibsrela |
| Tris Pharma INC | $28.73 | 2024 | Dyanavel Xr |
| Dexcom, INC. | $24.44 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $22.30 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $20.02 | 2023 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $18.40 | 2025 | Cobenfy |
| Exact Sciences Corporation | $16.97 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $15.08 | 2023 | Repatha, Otezla |
| Cumberland Pharmaceuticals, INC. | $13.93 | 2024 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.